![]()
|
|
||||||||
(Received for publication, January 28, 1997, and in revised form, February 12, 1997)
From the Department of Biochemistry and Molecular Biology, Mayo
Clinic Scottsdale, Scottsdale, Arizona 85259
We report the isolation of a cDNA encoding
the third putative hyaluronan synthase, HAS3. Partial cDNAs and
genomic fragments of mouse Has3 were obtained using a degenerate
polymerase chain reaction approach. Partial clones facilitated the
isolation of genomic and cDNA clones representing the mouse Has3
open reading frame. The open reading frame of 554 amino acids predicted
a protein of 63.3 kDa with multiple transmembrane domains and several
consensus HA binding motifs. Sequence comparisons indicated that mouse
Has3 is most closely related to Has2 (71% amino acid identity) and also related to Has1 (57% identity), Xenopus laevis DG42
(56% identity), and Streptococcus pyogenes HasA (28%
identity). Isolation of a genomic fragment of human HAS3 indicated high
conservation between mouse and human sequences, similar to those
observed for HAS1 and HAS2. Expression of the mouse Has3 open reading
frame in transfected COS-1 cells led to high levels of hyaluronan
synthesis, as determined through a classical particle exclusion assay,
and by in vitro HA synthase assays. These results suggest
that there are three putative mammalian hyaluronan synthases encoded by
three separate but related genes which comprise a mammalian hyaluronan synthase (HAS) gene family.
Hyaluronan (HA)1 is a linear
unbranched glycosaminoglycan (GAG) composed of repeating disaccharide
units of D-glucuronic
acid( While attempting to isolate fragments of the human HAS2 gene
using a degenerate PCR approach, we isolated fragments of an additional
related gene in the mouse and human. We now report the molecular
cloning and characterization of a cDNA encoding the third putative
mammalian hyaluronan synthase, HAS3.
Previously
described degenerate oligonucleotide primer pools (10), DEG 1 and DEG
5, were utilized in an attempt to amplify fragments of HAS genes from
human and mouse genomic DNA. PCR buffer conditions were as recommended
by the manufacturer (Boehringer Mannheim). The templates were 100 ng of
human T47D mammary carcinoma cell line genomic DNA and 100 ng of mouse
129Sv/J genomic DNA, prepared by standard procedures. Cycling
parameters were as follows: 35 cycles of 94 °C for 10 s,
50 °C for 30 s, and 72 °C for 1 min, followed by a final
extension step at 72 °C for 10 min. Amplified fragments of the
expected size were identified through agarose gel electrophoresis,
gel-purified, and cloned directly as described previously (10). Two
additional degenerate oligonucleotide primer pools (DEG 10 and DEG 11)
were designed, based upon the conserved amino acid sequences GWGTSGRK
and RWLNQQTRW (Ref. 10 and Fig. 2). Similar PCR conditions were used to
amplify fragments of the expected size from human and mouse genomic DNA
using these primers.
Based upon the sequence of partial fragments obtained as described
above, a single pair of oligonucleotide primers, forward 5 Nucleotide, amino acid sequence, and
embryonic expression of hyaluronan synthase 3. A, amino acid
alignment of a partial sequence for human HAS3 with the equivalent area
of mouse Has3. Conserved amino acids are indicated by a dash
(
The sequence obtained from analysis of genomic clones was confirmed
from cDNA sequence through the reverse transcriptase-polymerase chain reaction amplification, cloning, and sequencing of a mouse Has3
ORF cDNA from late gestation (17.5 days postcoitum) mouse C57BL/6J
embryo total RNA. Oligonucleotides possessed EcoRI
restriction endonuclease sites (underlined) at their 5 To determine the temporal expression pattern in the developing mouse
embryo, the mouse Has3 ORF cDNA was labeled with
[ The mouse
Has3 ORF, amplified and cloned as described above, was cloned into the
EcoRI site of the expression vector pCIneo (Promega,
Madison, WI). The mouse Has3 expression vector was co-transfected with
a pCMV Crude cell membrane preparations were isolated from COS-1 cells
transfected with the mouse Has3 expression vector, the mouse Has2
expression vector (10), and the pCIneo vector (control), essentially as
described (14), except the final membrane pellets were resuspended in
50 µl of lysis buffer (LB) consisting of 10 mM KCl, 1.5 mM MgCl2, and 10 mM Tris-HCl, pH
7.4, plus protease inhibitors (aprotinin, leupeptin, and
phenylmethylsulfonyl fluoride) (LB+). Protein content of crude membrane
preparations was determined by a BCA assay (Pierce). To detect HA
synthase activity, duplicate samples of approximately 100 µg of crude
membrane protein were incubated overnight at 37 °C in a total
reaction volume of 200 µl under the following conditions: 5 mM dithiothreitol, 15 mM MgCl2, 25 mM HEPES, pH 7.1, 1 mM UDP-GlcNAc, 0.05 mM UDP-GlcUA, 0.4 µg of aprotinin, 0.4 µg of leupeptin,
0.5 µCi of UDP-[14C]GlcUA (ICN, Costa Mesa, CA). An
additional specificity control reaction was set up in which UDP-GlcNAc
was omitted. After overnight incubation, samples were boiled for 10 min
and subsequently divided in two. Streptomyces hyaluronidase
(1 turbidity reducing unit) was added to one half and incubated for an
additional hour at 37 °C. SDS was added to a final concentration of
1%, and samples were boiled and analyzed by descending paper
chromatography essentially as described (15).
While cloning fragments of human HAS2, we isolated a
fragment of an additional gene that was related to but distinct from human HAS1 and HAS2. We isolated this fragment
through PCR amplification with previously described HAS-specific
degenerate oligonucleotide primers DEG 1 and DEG 5 (10). In contrast to
our previous studies in which we amplified off a cDNA template, in
this instance we used a genomic DNA template. HAS fragments were
amplified from human and mouse genomic DNA. Subsequent cloning and
sequence analyses revealed that all the human and mouse clones fell
into two categories. The first category represented clones of human and
mouse HAS2, while the second category of clones were highly conserved
between human and mouse, and represented fragments derived from a
related gene that was not HAS1 or HAS2. Subsequently, we used
additional combinations of degenerate primers to amplify and clone
additional fragments of this novel gene, which we have designated
HAS3 in humans and Has3 in the mouse (Fig.
1A). Alignment of the partial sequence of
human HAS3 and mouse Has3 indicated a very high level of sequence
conservation (99%) (Fig. 1A). This is similar to the high
level of conservation observed for human and mouse HAS1 (96%) and HAS2
(99%) (7-11).
Through genomic cloning and sequence analyses and confirmation of this
sequence from cDNA-derived clones, we identified an ORF of 1662 base pairs for mouse Has3 (Fig. 1B). This ORF encodes a
polypeptide of 554 amino acids with a predicted molecular mass of 63.3 kDa. This polypeptide is only 2 amino acids longer than the mouse Has2
polypeptide (10). Sequence alignments indicated that mouse Has3 is 71, 57, 56, and 28% identical to mouse Has2 (10), mouse Has1 (HAS protein)
(7), Xenopus DG42 (16), and S. pyogenes HasA
(17), respectively (Fig. 2A). Like Has1 and
Has2, residues demonstrated to be critical for
N-acetylglucosaminyltransferase activity of yeast chitin
synthase 2 (18) are completely conserved. In addition, these residues
are conserved with members of a recently identified putative plant
cellulose synthase family (19) (Fig. 2B).
Hydrophilicity plots suggested that Has3 is very similar in structure
to Has2 and Has1 and predicted the presence of multiple transmembrane
domains, with two at the N terminus and a cluster at the C terminus
(Fig. 2C). Significantly, like Has2 and Has1, the Has3
sequence predicts the presence of several potential HA binding motifs
defined by the consensus B(X7)B (20)
(underlined in Fig. 1B). Furthermore, these
motifs are located at similar positions within the Has3
polypeptide.
In contrast to mouse Has2, which is highly expressed from as early as
day 7.5 postcoitum through late gestation in the developing mouse
embryo (10), mouse Has3 is expressed predominantly in the late
gestation embryo (Fig. 1C). One major transcript of
approximately 6.0-6.5 kb and a minor transcript of approximately 4.0 kb were observed (Fig. 1C).
To test the enzyme activity of mouse Has3, we transfected an expression
vector carrying the Has3 ORF into COS-1 cells. We tested mouse Has3
alongside mouse Has2 and a negative control of vector alone. Expression
of mouse Has3 by COS-1 cells led to the generation of well pronounced
HA-dependent pericellular coats, as previously observed for
Has2 (10) (Fig. 3). To confirm the HA biosynthetic
capability of Has3-transfected cells, we performed HA synthase assays
on crude membranes prepared from these cells. These assays indicated
that crude membranes prepared from either Has3- or Has2-transfected
COS-1 cells were capable of converting UDP-[14C]GlcUA
into significant amounts of a high molecular weight product only in the
presence of UDP-GlcNAc (Table I). Furthermore, this product could be specifically degraded by Streptomyces
hyaluronidase (Table I). Thus, in COS-1 cells, Has2 and Has3 appear to
possess similar enzymatic activities and are therefore likely to
represent bona fide mammalian HA synthases.
Hyaluronan synthase activity of transfected COS-1 cells
Volume 272, Number 14,
Issue of April 4, 1997
pp. 8957-8961
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.
,
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES
1
3)N-acetylglucosamine(
1
4). HA is a major
constituent of the extracellular matrix of most tissues and organs,
especially during embryonic development, where it has been proposed to
play important roles in cell migration, proliferation, and the
development of tissue architecture (1-3). In addition, HA has been
implicated in tumorigenesis, and defects in HA metabolism are a
hallmark of several important diseases including rheumatoid arthritis,
Grave's ophthalmopathy, cirrhosis of the liver, and accelerated aging
in Werner's syndrome (1-4). Unlike other GAGs, which are synthesized
within the Golgi network and attached to protein, HA is synthesized at
the inner face of the plasma membrane and is subsequently extruded to
the outside of the cell (5, 6). Recently, we and others (7-11) have identified two mammalian genes, HAS1 and HAS2, encoding putative plasma
membrane HA synthases related to the Streptococcus pyogenes HA synthase, HasA. Expression of either HAS1 or HAS2 by cells led to
high levels of HA biosynthesis, consistent with both proteins playing
critical roles in HA biosynthesis, possibly as the HA synthases
themselves.
cDNA and Genomic Cloning and Expression
Fig. 2.
Comparison of mouse Has3 with related
enzymes. A, amino acid alignment of mouse Has3 with mouse
Has2 (MHas2), mouse Has1 (MHas1), Xenopus
laevis DG42 (DG42), and S. pyogenes HasA. Conserved residues are boxed. Gaps have been introduced to
maximize the alignment. Asterisks indicate positions at
which there have been significant conservative amino acid
substitutions. B, alignment of two regions of the mouse Has3
protein sequence with equivalent areas of related glycosyltransferases,
mouse Has2, mouse Has1, Xenopus DG42, S. pyogenes
HasA, R. meliloti NodC, Gossypium hirsutum putative cellulose synthase A1 (celA1), and S. cerevisiae chitin synthase 2 (Chs2). Site-directed
mutagenesis of the residues highlighted in bold of yeast
Chs2 resulted in loss of enzymatic activity (18), suggesting that these
residues may be critical for
1
4 glycosyltransferase activity.
C, Kyte-Doolittle hydrophilicity plots of mouse Has3, mouse
Has2, mouse Has1, and S. pyogenes HasA. Hydrophobic areas are represented below the axes. Potential transmembrane domains are
indicated by black bars drawn below each plot.
[View Larger Version of this Image (84K GIF file)]
-TAC TGG ATG
GCT TTC AAC GTG GAG-3
(corresponding to nucleotides 790-813, Fig.
1B) and reverse 5
-GTC ATC CAG AGG TGG TGC TTA TGG-3
(corresponding to antisense complement of nucleotides 1142-1119, Fig.
1B), was designed to facilitate PCR screening of a mouse 129Sv P1 genomic library (Genome Systems, St. Louis, MO). Three positive P1 clones were obtained, and restriction fragments spanning the entire mouse Has3 gene were identified and subcloned
into pBluescript (Stratagene, La Jolla, CA) based vectors using
standard procedures. Sequence analyses, using synthetic
oligonucleotides made to the mouse Has3 sequence and to vector
sequence, permitted the identification of the predicted mouse Has3 open
reading frame (ORF), based upon comparison with mouse Has1 and Has2
sequences (7, 10) and genomic structures.2
All sequences were determined from both DNA strands from multiple overlapping sequencing runs.
Fig. 1.
). B, nucleotide and predicted amino acid sequence of the
mouse Has3 open reading frame as derived from cDNA and genomic
clones. Sequences representing consensus HA binding motifs are
underlined. The location of three introns within the gene
are indicated by arrowheads. The first intron is located
immediately preceding the start codon (ATG). The partial human HAS3
sequence and the mouse Has3 ORF sequence described herein have been
deposited in GenBankTM and are available through accession
numbers U86409[GenBank] and U86408[GenBank], respectively. C, Northern blot
depicting the expression of mouse Has3 at four stages of mouse
embryonic development. A cDNA probe representing the mouse Has3 ORF
was radiolabeled and hybridized to a blot containing mouse embryonic
poly(A)+ RNAs (CLONTECH) under conditions recommended by
the manufacturer. Two transcripts, a major transcript of
approximately 6.0-6.5 kb and a minor transcript of approximately 4.0 kb, were
observed. Mouse Has3 expression appears to be highest in the late
gestation embryo (17.5 days postcoitum).
[View Larger Version of this Image (37K GIF file)]
termini to
facilitate subsequent cloning steps and had the following sequence:
forward, 5
-CCAAG ATG GCG GTG CAG CTG ACT ACA GCC-3
,
corresponding to nucleotides 1-24, Fig. 1B) and reverse,
5
-CC TCA CAC CTC CGC AAA AGC CAG GC-3
,
corresponding to the antisense complement of nucleotides 1665-1643,
Fig. 1B). First-strand cDNA synthesis was performed as
described (10) using the mouse Has3 reverse oligonucleotide primer.
First-strand cDNAs were PCR-amplified using standard PCR buffer
conditions supplemented with 2% deionized formamide, through 35 cycles
of 94 °C for 10 s, 65 °C for 30 s, and 72 °C for 2 min, followed by a final extension step of 72 °C for 10 min.
Amplified cDNAs of the expected size were gel-purified and cloned
as described previously. All sequence analyses were performed using the
Genetics Computer Group (GCG) package and MacVector programs.
32P]dCTP by random priming (12) and hybridized to a
Northern blot of mouse embryo messenger RNA (CLONTECH, Palo Alto, CA)
under conditions recommended by the manufacturer.
-gal vector into COS-1 (SV40-transformed African green monkey
kidney) cells using LipofectAMINETM (Life Technologies Inc.) according
to the manufacturer's instructions. Positive control transfections
utilized the mouse Has2 expression vector previously described (10). HA
coat assays (13) and detection of
-galactosidase activity were
performed as described (10).
Fig. 3.
Mouse Has3-transfected COS-1 cells generate
HA-dependent pericellular coats. COS-1 cells were
transfected with mouse Has2 pCIneo (A), pCIneo
(B), and mouse Has3 pCIneo (C-F) vectors. Addition of fixed horse erythrocytes to culture dishes permitted the
visualization of pericellular coats. Pericellular coats were produced
by mouse Has2-transfected cells (A) as described previously (10) and by mouse Has3-transfected cells (C and
E). pCIneo (vector only control) transfected cells failed to
produce coats (B). Mouse Has3-transfected cells produced
pericellular coats that were destroyed by treatment with a specific
hyaluronidase from Streptomyces (5 turbidity reducing
units/ml for 1 h at 37 °C) (compare panels E, before
hyaluronidase treatment, and F, after hyaluronidase treatment). In contrast, pericellular coats remained on mock
hyaluronidase-treated cells (compare panels C, before, and
D, after mock hyaluronidase treatment).
[View Larger Version of this Image (148K GIF file)]
Vector
+
UDP-GlcNAca
UDP-GlcNAcHyaluronidaseb
Mouse Has3
pCIneo
204.2c
1.9d
65.0
2.2
+
Mouse Has2
pCIneo
26.9
2.5
10.5
2.0
+
pCIneo
(control)
11.0
NDe
10.3
ND
+
a
Plus and minus symbols indicate whether or not
UDP-GlcNAc was included in these reactions.
b
Plus and minus symbols indicate whether or not a reaction
was subsequently treated for 1 h at 37 °C with 1 TRU
Streptomyces hyaluronidase prior to paper chromatography.
c
Numbers represent picomoles of radiolabeled product formed
and were calculated taking into account the specific activity of the
UDP-[14C]GlcUA used, the amount of cold UDP-GlcUA per
reaction, and assumed a scintillation counting efficiency of >95%.
Based upon these calculations, 1 pmol of radiolabeled product is
represented by 384 dpm, i.e. 204.2 pmol of product was
calculated from 78,413 dpm. Numbers represent the mean calculated from
duplicate reactions.
d
Number represents the result of a single reaction in each
instance.
e
Not determined.
Three mammalian putative hyaluronan synthases, HAS1, HAS2, and
HAS3, have now been identified. The three proteins are encoded by three
separate but related genes, which constitute a mammalian HAS gene
family. Sequence comparisons and structural predictions suggest that
the mammalian HAS proteins are very similar in structure. They are
predicted to have one or two N-terminal transmembrane domains and a
cluster of C-terminal transmembrane domains separated by a large
cytoplasmic loop. This topology is extraordinarily similar to that
predicted for the bacterial HA synthase, HasA (21), and to that
recently reported for the Rhizobium meliloti nodulation
factor, NodC (22). In addition, the mammalian HAS sequences, the
Xenopus DG42 sequence, HasA sequence, NodC sequence, and the
recently reported putative plant cellulose synthases share critical
residues shown to be required for
N-acetylglucosaminyltransferase activity of yeast chitin
synthase 2, making it highly likely that all these proteins are
functionally related processive
-glycosyltransferases. It has been
suggested that three similar regions containing highly conserved
aspartate (Asp) residues will be present in all such processive
glycosyltransferases ((23) and Fig. 2B). These highly conserved residues may represent sites such as cation binding sites
that in turn may coordinate nucleotide-sugar interaction with the
enzyme.
Semino et al. (24) have postulated that DG42 and its related mammalian homologues, rather than being bona fide HA synthases, may stimulate HA production through synthesizing chitin oligosaccharide primers, which are required and rate-limiting for eukaryotic HA biosynthesis. However, cell membranes isolated from bakers' yeast, Saccharomyces cerevisiae, engineered to express DG42 have HA synthesis activity in vitro when supplied with the required UDP precursors (25). This is highly significant as S. cerevisiae is deficient in UDP-glucuronic acid production and is thus incapable of HA biosynthesis. This result and ours suggest that DG42 and its related mammalian counterparts are bona fide eukaryotic hyaluronan synthases. Clearly, however, this is an area that must be thoroughly examined in future experiments by, for instance, purifying the enzyme activities.
Expression of any one of the mammalian HAS proteins in transfected mammalian cells leads to a dramatic increase in HA biosynthesis. This would suggest that the proteins have similar activities. However, the high degree of sequence conservation (96-99% identity) between human and mouse HA synthases contrasts with the lower level of identity between synthases within a species (Has1/Has2, 55% identity; Has1/Has3, 57% identity; Has2/Has3, 71% identity), arguing for evolutionary conservation of functionally important residues and for some differences in the mode of action of the three proteins. Potential differences in function of the proteins could relate to the length of the HA chain synthesized, the rate of HA synthesis, the ability to interact with cell-type specific accessory proteins, and whether or not the HA is preferentially secreted by the cell or alternatively retained by the cell in the form of a pericellular coat.
In conclusion, a small gene family encoding putative plasma membrane hyaluronan synthases is present in mammals. We have recently determined that the mouse and human HAS genes are localized on three separate autosomes (26). Our data suggest that a primitive ancestral HA synthase gene duplicated comparatively early in vertebrate evolution, and that the HAS genes have subsequently diverged with respect to the regulatory sequences controlling their expression and possibly with respect to their mode of action. This in turn would suggest that HA biosynthesis is regulated at many levels within the vertebrate organism.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) U86408[GenBank] (mouse Has3) and U86409[GenBank] (human HAS3).
To whom correspondence may be addressed: Dept. of Biochemistry and
Molecular Biology, Mayo Clinic Scottsdale, 13400 East Shea Blvd.,
Scottsdale, AZ 85259. Tel.: 602-301-8859; Fax: 602-301-7017; E-mail:
spicer{at}mayo.edu or mcdonald{at}mayo.edu.
We acknowledge Jill Martin within the Molecular Biology Core Facility at Mayo Clinic Scottsdale for her oligonucleotide synthesis and the graphical expertise of Marv Ruona. We also acknowledge all members of the McDonald Laboratory, Mayo Clinic Scottsdale for helpful discussions and support.
This article has been cited by other articles:
![]() |
N. Borg and M. Holland The effect of glycosaminoglycans on rat gametes in vitro and the associated signal pathway Reproduction, March 1, 2008; 135(3): 311 - 319. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. H. Weigel and P. L. DeAngelis Hyaluronan Synthases: A Decade-plus of Novel Glycosyltransferases J. Biol. Chem., December 21, 2007; 282(51): 36777 - 36781. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Monslow, J. D. Williams, D. J. Fraser, D. R. Michael, P. Foka, A. P. Kift-Morgan, D. D. Luo, C. A. Fielding, K. J. Craig, N. Topley, et al. Sp1 and Sp3 Mediate Constitutive Transcription of the Human Hyaluronan Synthase 2 Gene J. Biol. Chem., June 30, 2006; 281(26): 18043 - 18050. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Straach, J. M. Shelton, J. A. Richardson, V. C. Hascall, and M. S. Mahendroo Regulation of hyaluronan expression during cervical ripening Glycobiology, January 1, 2005; 15(1): 55 - 65. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Monslow, J. D. Williams, C. A. Guy, I. K. Price, K. J. Craig, H. J. Williams, N. M. Williams, J. Martin, S. L. Coleman, N. Topley, et al. Identification and Analysis of the Promoter Region of the Human Hyaluronan Synthase 2 Gene J. Biol. Chem., May 14, 2004; 279(20): 20576 - 20581. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Takeo, M. Fujise, T. Akiyama, H. Habuchi, N. Itano, T. Matsuo, T. Aigaki, K. Kimata, and H. Nakato In Vivo Hyaluronan Synthesis upon Expression of the Mammalian Hyaluronan Synthase Gene in Drosophila J. Biol. Chem., April 30, 2004; 279(18): 18920 - 18925. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sussmann, M. Sarbia, J. Meyer-Kirchrath, R.M. Nusing, K. Schror, and J.W. Fischer Induction of Hyaluronic Acid Synthase 2 (HAS2) in Human Vascular Smooth Muscle Cells by Vasodilatory Prostaglandins Circ. Res., March 19, 2004; 94(5): 592 - 600. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Hoshi, H. Nakagawa, S. Nishiguchi, K. Iwata, K. Niikura, K. Monde, and S.-I. Nishimura An Engineered Hyaluronan Synthase: CHARACTERIZATION OF RECOMBINANT HUMAN HYALURONAN SYNTHASE 2 EXPRESSED IN ESCHERICHIA COLI J. Biol. Chem., January 23, 2004; 279(4): 2341 - 2349. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Mascarenhas, R. M. Day, C. D. Ochoa, W.-I. Choi, L. Yu, B. Ouyang, H. G. Garg, C. A. Hales, and D. A. Quinn Low Molecular Weight Hyaluronan from Stretched Lung Enhances Interleukin-8 Expression Am. J. Respir. Cell Mol. Biol., January 1, 2004; 30(1): 51 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. S. Prabhakar, R. S. Bahn, and T. J. Smith Current Perspective on the Pathogenesis of Graves' Disease and Ophthalmopathy Endocr. Rev., December 1, 2003; 24(6): 802 - 835. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Marchal, M. Caillaud, A. Martoriati, N. Gerard, P. Mermillod, and G. Goudet Effect of Growth Hormone (GH) on In Vitro Nuclear and Cytoplasmic Oocyte Maturation, Cumulus Expansion, Hyaluronan Synthases, and Connexins 32 and 43 Expression, and GH Receptor Messenger RNA Expression in Equine and Porcine Species Biol Reprod, September 1, 2003; 69(3): 1013 - 1022. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schoenfelder and R. Einspanier Expression of Hyaluronan Synthases and Corresponding Hyaluronan Receptors Is Differentially Regulated During Oocyte Maturation in Cattle Biol Reprod, July 1, 2003; 69(1): 269 - 277. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Nilsson, D. N. Haylock, H. M. Johnston, T. Occhiodoro, T. J. Brown, and P. J. Simmons Hyaluronan is synthesized by primitive hemopoietic cells, participates in their lodgment at the endosteum following transplantation, and is involved in the regulation of their proliferation and differentiation in vitro Blood, February 1, 2003; 101(3): 856 - 862. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kimura, Y. Konno, K. Miyoshi, H. Matsumoto, and E. Sato Expression of Hyaluronan Synthases and CD44 Messenger RNAs in Porcine Cumulus-Oocyte Complexes During In Vitro Maturation Biol Reprod, March 1, 2002; 66(3): 707 - 717. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Liu, F. Gao, Z. Han, X. Xu, C. B. Underhill, and L. Zhang Hyaluronan Synthase 3 Overexpression Promotes the Growth of TSU Prostate Cancer Cells Cancer Res., July 1, 2001; 61(13): 5207 - 5214. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Usui, S. Amano, T. Oshika, K. Suzuki, K. Miyata, M. Araie, P. Heldin, and H. Yamashita Expression Regulation of Hyaluronan Synthase in Corneal Endothelial Cells Invest. Ophthalmol. Vis. Sci., October 1, 2000; 41(11): 3261 - 3267. [Abstract] [Full Text] |
||||
![]() |
Y. Li, M. Rahmanian, C. Widström, G. Lepperdinger, G. I. Frost, and P. Heldin Irradiation-Induced Expression of Hyaluronan (HA) Synthase 2 and Hyaluronidase 2 Genes in Rat Lung Tissue Accompanies Active Turnover of HA and Induction of Types I and III Collagen Gene Expression Am. J. Respir. Cell Mol. Biol., September 1, 2000; 23(3): 411 - 418. [Abstract] [Full Text] |
||||
![]() |
K. A. Fitzgerald, A. G. Bowie, B. S. Skeffington, and L. A. J. O'Neill Ras, Protein Kinase C{zeta}, and I{kappa}B Kinases 1 and 2 Are Downstream Effectors of CD44 During the Activation of NF-{kappa}B by Hyaluronic Acid Fragments in T-24 Carcinoma Cells J. Immunol., February 15, 2000; 164(4): 2053 - 2063. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yoshida, N. Itano, Y. Yamada, and K. Kimata In Vitro Synthesis of Hyaluronan by a Single Protein Derived from Mouse HAS1 Gene and Characterization of Amino Acid Residues Essential for the Activity J. Biol. Chem., January 7, 2000; 275(1): 497 - 506. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Kaback and T. J. Smith Expression of Hyaluronan Synthase Messenger Ribonucleic Acids and Their Induction by Interleukin-1{beta} in Human Orbital Fibroblasts: Potential Insight into the Molecular Pathogenesis of Thyroid-Associated Ophthalmopathy J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4079 - 4084. [Abstract] [Full Text] |
||||
![]() |
N. Itano, T. Sawai, M. Yoshida, P. Lenas, Y. Yamada, M. Imagawa, T. Shinomura, M. Hamaguchi, Y. Yoshida, Y. Ohnuki, et al. Three Isoforms of Mammalian Hyaluronan Synthases Have Distinct Enzymatic Properties J. Biol. Chem., August 27, 1999; 274(35): 25085 - 25092. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Smith and S. J. Parikh HMC-1 Mast Cells Activate Human Orbital Fibroblasts in Coculture: Evidence for Up-Regulation of Prostaglandin E2 and Hyaluronan Synthesis Endocrinology, August 1, 1999; 140(8): 3518 - 3525. [Abstract] [Full Text] |
||||
![]() |
M. S. Buckeridge, C. E. Vergara, and N. C. Carpita The Mechanism of Synthesis of a Mixed-Linkage (1right-arrow3),(1right-arrow4)beta -D-Glucan in Maize. Evidence for Multiple Sites of Glucosyl Transfer in the Synthase Complex Plant Physiology, August 1, 1999; 120(4): 1105 - 1116. [Abstract] [Full Text] |
||||
![]() |
Y. Nishida, C. B. Knudson, J. J. Nietfeld, A. Margulis, and W. Knudson Antisense Inhibition of Hyaluronan Synthase-2 in Human Articular Chondrocytes Inhibits Proteoglycan Retention and Matrix Assembly J. Biol. Chem., July 30, 1999; 274(31): 21893 - 21899. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Cao, H.-S. Wang, Y. Zhang, H.-Y. Lin, R. P. Phipps, and T. J. Smith Activation of Human Orbital Fibroblasts through CD40 Engagement Results in a Dramatic Induction of Hyaluronan Synthesis and Prostaglandin Endoperoxide H Synthase-2 Expression. INSIGHTS INTO POTENTIAL PATHOGENIC MECHANISMS OF THYROID-ASSOCIATED OPHTHALMOPATHY J. Biol. Chem., November 6, 1998; 273(45): 29615 - 29625. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. L. Tlapak-Simmons, E. S. Kempner, B. A. Baggenstoss, and P. H. Weigel The Active Streptococcal Hyaluronan Synthases (HASs) Contain a Single HAS Monomer and Multiple Cardiolipin Molecules J. Biol. Chem., October 2, 1998; 273(40): 26100 - 26109. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Spicer, L. A. Kaback, T. J. Smith, and M. F. Seldin Molecular Cloning and Characterization of the Human and Mouse UDP-Glucose Dehydrogenase Genes J. Biol. Chem., September 25, 1998; 273(39): 25117 - 25124. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Spicer and J. A. McDonald Characterization and Molecular Evolution of a Vertebrate Hyaluronan Synthase Gene Family J. Biol. Chem., January 23, 1998; 273(4): 1923 - 1932. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kumari and P. H. Weigel Molecular Cloning, Expression, and Characterization of the Authentic Hyaluronan Synthase from Group C Streptococcus equisimilis J. Biol. Chem., December 19, 1997; 272(51): 32539 - 32546. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. H. Weigel, V. C. Hascall, and M. Tammi Hyaluronan Synthases J. Biol. Chem., May 30, 1997; 272(22): 13997 - 14000. [Full Text] [PDF] |